{"entity":{"id":"xerient","kind":"company","name":"Xerient","aka":["Xerient Pharma"],"tldr":"Xerient develops a way to protect the bowel next to the pancreas during radiotherapy, so that pancreatic tumours can be treated with radiation more safely. Its XER-001 is in an early trial with stereotactic radiotherapy for locally advanced pancreatic cancer.","summary":"Xerient is based in Houston, Texas, and focuses on abdominal and gastrointestinal cancers. XER-001 repurposes an already approved drug, amifostine, delivered through a nasoduodenal route, to protect the duodenum during radiotherapy. The phase 1/2a trial NCT07157033 combines XER-001 with stereotactic body radiotherapy in locally advanced pancreatic adenocarcinoma, at sites including City of Hope and Karmanos Cancer Institute. Its first registered cancer trial, NCT07157033, was posted on ClinicalTrials.gov in September 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://xerient.net/"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":["radiation","supportive-care"],"technologies":["radioprotectors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07157033"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The active ingredient and delivery route come from the registry record; the company website describes XER-001 only as a repurposed FDA-approved drug that protects the duodenum.","Founding year and financing not stated on the company website.","The registry contact domain belongs to AccelSoBio, an oncology clinical research firm; xerient.net is the company's own site, reached by redirect from xerientpharma.com.","Company website read on 29 October 2026."],"hq":"Houston, TX","country":"US","companyType":"biotech","website":"https://xerient.net/","investors":[],"funding":[]},"route":"/companies/xerient/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"technology":[{"id":"radioprotectors","kind":"technology","name":"Radioprotectors and normal-tissue sparing drugs","route":"/technologies/radioprotectors/"}],"trial":[{"id":"nct07157033","kind":"trial","name":"A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.","route":"/trials/nct07157033/"}]}}